SCHEMBL8588461

SCHEMBL8588461

Nc1cccc2ccc(CO)nc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 2/20 0.63
PDE10A Q9Y233 4/20 0.43
PARP1 P09874 1/20 0.42
HTR3A P46098 1/20 0.41
NCF1 P14598 3/20 0.40
PLAU P00749 2/20 0.40
BACE1 P56817 1/20 0.36
HSD17B10 Q99714 2/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP3A4 P08684 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
KEAP1 Q14145 1/20 0.34
ELANE P08246 1/20 0.34
MPO P05164 1/20 0.34
KDM4E B2RXH2 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
MAPT P10636 1/20 0.33
HIF1A Q16665 1/20 0.33
MCHR1 Q99705 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27835947 0.82 PDE10A (0.44) CCR1PDE10APARP1HTR3ANCF1
SCHEMBL26053800 0.81 PARP1 (0.58) CCR1PDE10APARP1HTR3ANCF1
SCHEMBL1507709 0.79 PDE10A (0.42) CCR1PDE10APARP1HTR3ANCF1
SCHEMBL1507910 0.79 PDE10A (0.42) CCR1PDE10APARP1HTR3ANCF1
SCHEMBL30461061 0.79 PARP1 (0.49) CCR1PDE10APARP1HTR3ANCF1
SCHEMBL5301328 0.79 CCR1 (1.00) CCR1PDE10APARP1CYP3A4TSHR
SCHEMBL9220073 0.78 CCR1 (0.65) CCR1PDE10ANCF1PLAUHSD17B10
SCHEMBL28722027 0.77 CCR1 (0.63) CCR1PDE10APARP1NCF1PLAU
SCHEMBL7806536 0.77 CCR1 (0.63) CCR1PDE10APARP1ALDH1A1KDM4E
SCHEMBL30471553 0.77 PDE10A (0.43) CCR1PDE10APARP1HTR3AELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140335019-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND ANALYSIS OF NEUROLOGICAL DISORDERS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2014-11-13 US disclosed
US-8709743-B2 Inhibitors of bacterial nitric oxide synthase, and related screening methods MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2014-04-29 US disclosed
US-20110201042-A1 Inhibitors of Bacterial Nitric Oxide Synthase, and Related Screening Methods MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2011-08-18 US disclosed
US-7494821-B2 Fluorescein based sensors for tracking nitric oxide in live cells MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2009-02-24 US disclosed
US-20090017552-A1 FLUORESCEIN BASED SENSORS FOR TRACKING NITRIC OXIDE IN LIVE CELLS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2009-01-15 US disclosed
EP-0876345-A1 HETEROCYCLIC COMPOUNDS AS H+-ATPASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-11-11 EP disclosed
WO-1997014681-A1 HETEROCYCLIC COMPOUNDS AS H+-ATPASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140335019-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND ANALYSIS OF NEUROLOGICAL DISORDERS PSEN1, PSEN2, APP CCR1 4747/4885PDE10A 1490/4885PARP1 3777/4885
US-20110201042-A1 Inhibitors of Bacterial Nitric Oxide Synthase, and Related Screening Methods NOS1, NOS2, NOS3 CCR1 4605/4885PDE10A 150/4885PARP1 4359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.